Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345211 | 0.84 | GOT1 (0.62) | GOT1MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL30082487 | 0.84 | IDO1 (0.47) | MAPTALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL350637 | 0.84 | IDO1 (0.47) | MAPTALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL29365992 | 0.84 | GOT1 (0.62) | GOT1MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL27758703 | 0.82 | GOT1 (0.60) | GOT1MAPTALDH1A1SMN1; SMN2HPGD | |
| Hydrazine SCHEMBL10949625 | 0.79 | KDM4E (0.46) | MAPTALDH1A1SMN1; SMN2HPGDMEN1 | |
| Bicarbonate SCHEMBL11022555 | 0.78 | GOT1 (0.52) | GOT1MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL31617120 | 0.76 | PDE5A (0.38) | MAPTALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL10906806 | 0.74 | GOT1 (0.48) | GOT1MAPTALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL25254434 | 0.74 | EP300 (0.40) | MAPTKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190298717-A1 | Hydralazine and Active Derivatives Thereof for Neuronal Cell Survival and Regeneration | UNIV TEXAS (US) | 2019-10-03 | — | — | US | claimed |
| WO-2017160864-A1 | HYDRALAZINE AND ACTIVE DERIVATIVES THEREOF FOR NEURONAL CELL SURVIVAL AND REGENERATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-21 | — | — | WO | claimed |
| EP-4735433-A2 | SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF | Viva Star Biosciences (US) Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006681-A2 | SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF | VIVA STAR BIOSCIENCES (US) INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-3189049-B1 | PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117659025-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-03-08 | — | — | CN | disclosed |
| CN-117586108-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-117586191-A | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2024-02-23 | — | — | CN | disclosed |
| CN-111542515-B | TOLL-like receptor 8 (TLR 8) specific antagonists, methods of making and uses thereof | 科罗拉多州立大学董事会法人团体 | 2023-12-05 | — | — | CN | disclosed |
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | UNIV COLORADO REGENTS (US) | 2023-04-27 | — | — | US | disclosed |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2012151195-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-08 | — | — | WO | disclosed |
| US-8273742-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| CN-102459233-A | Disubstituted phthalazine hedgehog pathway antagonists | LILLY CO ELI (US) | 2012-05-16 | — | — | CN | disclosed |
| EP-2443104-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | Eli Lilly and Company (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-1505963-B9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-1505963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-20 | — | — | EP | disclosed |
| US-20100324048-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010147917-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324048-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | GOT1 3692/4885MAPT 3122/4885ALDH1A1 2679/4885 |
| US-20190298717-A1 | Hydralazine and Active Derivatives Thereof for Neuronal Cell Survival and Regeneration | GSK3B, MAPT, GSK3A | GOT1 543/4885MAPT 2/4885ALDH1A1 1374/4885 |
| US-20230132035-A1 | Toll-Like Receptor 8 (TLR8)-Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | GOT1 2941/4885MAPT 4277/4885ALDH1A1 4565/4885 |
| US-11466010-B2 | Toll-like receptor 8 (TLR8) specific antagonists and methods of making and uses thereof | TLR8, TLR3, TLR9 | GOT1 2762/4885MAPT 4286/4885ALDH1A1 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.